Free Trial
NASDAQ:BFRI

Biofrontera (BFRI) Stock Price, News & Analysis

$1.24
+0.14 (+12.73%)
(As of 07/26/2024 ET)
Today's Range
$1.08
$1.26
50-Day Range
$0.83
$1.24
52-Week Range
$0.61
$12.56
Volume
73,525 shs
Average Volume
381,178 shs
Market Capitalization
$6.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00

Biofrontera MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,351.6% Upside
$18.00 Price Target
Short Interest
Healthy
1.10% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.21) to ($0.23) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.55 out of 5 stars

BFRI stock logo

About Biofrontera Stock (NASDAQ:BFRI)

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

BFRI Stock Price History

BFRI Stock News Headlines

NEW AI developed by trader who won 1,129% (in 2 days)
Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...
NEW AI developed by trader who won 1,129% (in 2 days)
Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...
Biofrontera Inc. (NASDAQ:BFRI): Is Breakeven Near?
See More Headlines
Receive BFRI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/15/2024
Today
7/26/2024
Next Earnings (Estimated)
8/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BFRI
Fax
N/A
Employees
70
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.00
High Stock Price Target
$18.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+1,363.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-20,130,000.00
Pretax Margin
-69.41%

Debt

Sales & Book Value

Annual Sales
$34.07 million
Book Value
$3.16 per share

Miscellaneous

Free Float
5,078,000
Market Cap
$6.26 million
Optionable
No Data
Beta
0.44
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

Key Executives

  • Dr. Hermann Luebbert Ph.D. (Age 68)
    CEO, President & Executive Chairman
    Comp: $733.23k
  • Mr. Eugene Frederick Leffler III (Age 39)
    Chief Financial Officer
    Comp: $378.58k
  • Ms. Erica F. Gates CPA
    M.B.A., Senior Director of Finance & Principal Accounting Officer
  • Mr. Jon Lyons M.B.A.
    Ph.D., Vice President of Scientific & Medical Affairs
  • Ms. Alycia Torres
    Vice President of Administration
  • Mr. Daniel Hakansson J.D.
    General Counsel & Head of Compliance
  • Ms. Samantha Widdicombe
    Senior Director of Strategic Accounts & Communications
  • Mr. Mark Baldyga
    Vice President of Sales & Marketing

BFRI Stock Analysis - Frequently Asked Questions

How have BFRI shares performed this year?

Biofrontera's stock was trading at $2.77 at the beginning of the year. Since then, BFRI shares have decreased by 55.2% and is now trading at $1.24.
View the best growth stocks for 2024 here
.

How were Biofrontera's earnings last quarter?

Biofrontera Inc. (NASDAQ:BFRI) announced its earnings results on Wednesday, May, 15th. The company reported ($1.85) earnings per share for the quarter, missing analysts' consensus estimates of ($1.63) by $0.22. The business had revenue of $7.91 million for the quarter, compared to analysts' expectations of $11.52 million. Biofrontera had a negative trailing twelve-month return on equity of 1,390.99% and a negative net margin of 69.44%.

When did Biofrontera's stock split?

Biofrontera's stock reverse split on Wednesday, July 5th 2023. The 1-20 reverse split was announced on Wednesday, July 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Biofrontera IPO?

Biofrontera (BFRI) raised $19 million in an initial public offering (IPO) on Friday, October 29th 2021. The company issued 3,100,000 shares at $5.00-$7.00 per share. Roth Capital Partners and The Benchmark Company served as the underwriters for the IPO.

How do I buy shares of Biofrontera?

Shares of BFRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BFRI) was last updated on 7/26/2024 by MarketBeat.com Staff

From Our Partners